Your doctor says your cholesterol is "fine." Your LDL came back at 95 mg/dL, comfortably under the line. You train five days a week, you sleep well, your ring says your recovery is green. And yet a different number — one that was not on the panel — may be telling a completely different story about what is happening inside your arteries.
That number is ApoB, and in March 2026 it moved from biohacker forums into the official American cardiology guidelines. Here is what it measures, when it disagrees with your LDL, and what to do if yours comes back high.
What ApoB actually measures
Cholesterol does not float freely in blood. It is cargo, packed inside lipoprotein particles that ferry it around the body. The standard lipid panel measures the cargo: LDL-C tells you how much cholesterol is riding inside your LDL particles. It says nothing about how many particles are doing the carrying.
Apolipoprotein B is the structural protein wrapped around every artery-damaging particle: LDL, VLDL, IDL, remnants, and Lp(a). The key fact is simple and worth memorising: there is exactly one ApoB molecule per particle. Measure ApoB and you have counted the particles directly.
Why does the count matter more than the cargo? Because atherosclerosis is a traffic problem, not a tonnage problem. Particles cause damage by crossing into the artery wall and getting stuck there. A particle's odds of getting stuck do not depend much on how full it is. Ten half-empty trucks do more damage than five full ones, even though the total cargo is the same.
When your LDL and your ApoB disagree
Most of the time the two track each other, and if they agree, either one works fine. The interesting cases are the ones where they split apart — what researchers call discordance. And when they disagree, the evidence says your real risk follows the ApoB.
Discordance runs in both directions:
- Normal LDL-C, high ApoB. This is the dangerous version — the person who is told they are fine and is not. It happens when your particles are small and cholesterol-depleted, so it takes more of them to carry the same cholesterol load. In people with metabolic syndrome whose LDL-C was already at target, roughly a quarter still had ApoB above the recommended range. Across broader clinic populations the figure is often quoted at 15 to 20%.
- High LDL-C, normal ApoB. Also common. One study of people with metabolic disorders found around half had discordantly normal ApoB despite an elevated LDL-C — large, cholesterol-rich particles inflating the LDL-C reading without a matching particle count.
The pattern behind the first case is worth knowing, because it maps onto a specific metabolic picture: elevated triglycerides, low HDL, insulin resistance, and small dense LDL particles. If your triglycerides run above 150 mg/dL, if your fasting insulin is creeping up, or if your CGM shows glucose spikes that take hours to settle, you are exactly the person whose LDL-C is most likely to under-report the truth.
What the evidence shows — and where it is contested
This is where honesty matters, because ApoB has become a wellness-marketing buzzword and the real picture is strong but not unanimous.
What is well established: ApoB-containing particles cause atherosclerosis. This is not merely a correlation argument. Mendelian randomisation studies — which use inherited genetic variants as a kind of natural randomised trial, sidestepping the confounding that plagues nutrition research — consistently show a causal link between ApoB and both coronary disease and large-artery stroke. Head to head, ApoB generally outperforms LDL-C as a risk predictor; a 2025 review found it did so in every study examined. Long-running cohorts such as the 20-year ATTICA study point the same way.
Where researchers still argue: whether it is the particle count specifically, or the total cholesterol mass those particles carry, that does the damage. A 2022 Mendelian randomisation analysis in the European Journal of Preventive Cardiology concluded the causal signal tracked non-HDL cholesterol more closely than ApoB particle concentration. That is a real, unsettled scientific dispute — not a reason to ignore ApoB, but a reason to be sceptical of anyone selling particle number as the single master variable.
What is not established: that ApoB replaces everything else. It says nothing about inflammation, blood pressure, insulin resistance, or Lp(a). It is one strong input, not a verdict.
A specific warning for the keto and carnivore crowd
If you went low-carb, watched your LDL and ApoB climb, and were reassured by the "Lean Mass Hyper-Responder" argument — that a high ApoB does not matter if you are lean and insulin-sensitive with high HDL and low triglycerides — you should know what happened to the study behind that claim.
The KETO-CTA paper, published in JACC: Advances in 2025 under the title "Plaque Begets Plaque, ApoB Does Not," reported that ApoB failed to predict plaque progression in this group. The journal issued an Expression of Concern, and the paper was retracted in 2026 after concerns about methodology and selective reporting: the pre-registered primary outcome, change in non-calcified plaque volume, was set aside in favour of a secondary endpoint. Meanwhile the participants themselves — median LDL-C around 237 mg/dL — showed meaningful plaque progression over the study year.
The honest read: being lean and metabolically healthy does not appear to neutralise a very high ApoB. If a dietary change has pushed your ApoB above 130 mg/dL, that deserves a conversation with a physician rather than a forum consensus.
How to read your ApoB number
Labs usually flag anything up to 100 mg/dL as "normal," but normal is a population average taken from a population with a great deal of heart disease. Optimal is lower. The most widely used targets come from the 2019 ESC/EAS guidelines, which set ApoB goals alongside LDL-C goals:
- Under 65 mg/dL — very high risk (existing cardiovascular disease). Pairs with an LDL-C goal under 55.
- Under 80 mg/dL — high risk. Pairs with an LDL-C goal under 70.
- Under 100 mg/dL — moderate risk. Pairs with an LDL-C goal under 100.
- 130 mg/dL and above — treated as a risk-enhancing finding in its own right, whatever your LDL-C says.
For a healthy adult with no other risk factors, most lipid specialists treat somewhere below 80 mg/dL as a reasonable aim — with the caveat that no trial has randomised low-risk people to a specific ApoB target. That number is an extrapolation from risk data, not a proven finish line.
What changed in the 2026 guidelines
In March 2026 the ACC and AHA published the first full update to US lipid guidance in eight years, retitled the Guideline on the Management of Dyslipidemia. Three changes matter for anyone tracking their own markers:
- ApoB is now formally recommended — selectively. It is endorsed to assess residual risk once LDL-C and non-HDL-C goals are met, particularly for people with type 2 diabetes, cardiovascular-kidney-metabolic syndrome, triglycerides at or above 150 mg/dL, or established cardiovascular disease. Note what this is not: the US guideline stops short of setting numeric ApoB targets, which is why the European figures above remain the practical reference.
- Lp(a) should be measured at least once in a lifetime. It is largely genetic and barely moves with lifestyle, so one test answers the question for good. Levels at or above 125 nmol/L (50 mg/dL) carry roughly 1.4 times the risk; at 250 nmol/L, at least double.
- The old Pooled Cohort Equations are retired in favour of the PREVENT calculator, which adds kidney function, drops race as an input, and projects risk 30 years out rather than 10.
Numeric treatment goals returned as well: LDL-C under 100, under 70, and under 55 mg/dL for borderline/intermediate, high, and very high risk respectively.
How to lower ApoB, ranked by effect size
The lifestyle levers are real but bounded. Diet, exercise, and weight loss together move ApoB by roughly 10 to 20%. That is meaningful if you are at 95 and want to be at 80. It will not take you from 140 to 65.
- Swap saturated fat for unsaturated fat. The single biggest dietary lever. Cutting saturated fat below about 6% of calories lowers ApoB by roughly 8 mg/dL in clinical trials. More olive oil, nuts, and fatty fish; less butter and fatty red meat.
- Soluble fibre, 10 g or more per day. Psyllium, oats, legumes, flaxseed. It works by binding bile acids in the gut, and meta-analyses of randomised trials show a consistent ApoB reduction in the region of 5%.
- Aerobic and resistance training. A modest independent effect, around 5 to 10% with consistent training — smaller than most lifters expect, and largely working through body composition and insulin sensitivity rather than on the particles directly.
- Fix the metabolic picture. If your ApoB is high because of insulin resistance and high triglycerides, cutting visceral fat and improving glucose control shifts particle size and particle count together.
- Medication. Statins, ezetimibe, and PCSK9 inhibitors lower ApoB far more than any lifestyle change can. If your number is high and your risk is real, that is a conversation to have rather than avoid.
One practical note that trips people up: give it 8 to 12 weeks. ApoB reflects a sustained pattern, not last week's effort. Retesting after ten days of clean eating tells you nothing but noise.
When to test
ApoB does not require fasting, which makes it easier to add than most people assume, and it costs little. A reasonable approach for anyone tracking their own health: measure it once as a baseline alongside a standard lipid panel, and measure Lp(a) once, ever. If your ApoB is at goal and nothing has changed, once a year is enough. If you are actively working on it — a diet change, a new medication, meaningful weight loss — retest at 8 to 12 weeks so you are measuring the intervention and not the noise.
The most useful thing you can do is read ApoB and LDL-C side by side. If they agree, you have a clean signal and can stop worrying about which one is right. If they disagree, you have just learned something your standard panel was hiding.
This article is educational content, not medical advice. Lipid targets depend on your whole risk picture, and decisions about testing or treatment belong with a qualified clinician who knows your history.
A single ApoB reading is a snapshot. What actually predicts how you age is the trend — how particle count, triglycerides, fasting insulin, and inflammation move together over years. VitalNexa tracks your biomarkers over time, syncs your wearable and glucose data alongside them, and turns the whole picture into one VitalNexa Biological Age you can watch respond to what you change. Get started free and see what your numbers have been trying to tell you.